Selected Milestones in Antiviral Drug Development

Erik De Clercq

DOI: https://doi.org/10.3390/v16020169

2024-01-24

Viruses

Abstract:This review article will describe the (wide) variety of approaches that I envisaged to develop a specific therapy for viral infections: (i) interferon and its inducers, (ii) HSV, VZV and CMV inhibitors, (iii) NRTIs (nucleoside reverse transcriptase inhibitors), NtRTIs (nucleotide reverse transcriptase inhibitors) and NNRTIs (non-nucleoside reverse transcriptase inhibitors) as HIV inhibitors, (iv) NtRTIs as HBV inhibitors, and finally, (v) the transition of an HIV inhibitor to a stem cell mobilizer, as exemplified by AMD-3100 (Mozobil®).

virology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

The paper "Selected Milestones in Antiviral Drug Development" aims to review and describe important milestones in antiviral drug development. Specifically, the author Erik De Clercq attempts to solve key problems in antiviral treatment in the following aspects:

1. **Interferons and their inducers**:
- Describes the role of interferons (IFN) and their inducers in antiviral treatment.
- Introduces the research on polyacrylic acid (PAA) and polymethacrylic acid (PMEA) as interferon inducers, and discusses their antiviral potential and toxicity issues.

2. **HSV, VZV and CMV inhibitors**:
- Discusses the development of inhibitors against herpes simplex virus (HSV), varicella - zoster virus (VZV) and cytomegalovirus (CMV).
- Specifically mentions the discovery and clinical application of compounds such as DHPA and BVDU.

3. **Nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs) and non - nucleoside reverse transcriptase inhibitors (NNRTIs) as HIV inhibitors**:
- Introduces in detail the discovery process of compounds such as AZT, d4T, HEPT and TIBO and their applications in HIV treatment.
- Discusses the mechanisms, toxicity and clinical development paths of these compounds.

4. **HBV inhibitors**:
- Mentions the application of NtRTIs as hepatitis B virus (HBV) inhibitors.

5. **The transition from HIV inhibitors to stem cell mobilizers**:
- Taking AMD - 3100 (Mozobil®) as an example, describes how some HIV inhibitors are re - positioned for other uses, such as stem cell mobilizers.

### Summary

By reviewing these important milestones in antiviral drug development, the paper aims to provide a comprehensive historical perspective, showing the discovery, mechanism research, clinical trials and final market applications of these drugs. This not only helps to understand the development process of antiviral drugs, but also provides valuable references for future antiviral research.